The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions.
The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.
Adult patients (greater than 18 years of age) diagnosed with pancreatic cancer that are eligible for soft tissue ablation per the treating physician.
Have a cardiac pacemaker or ICD implant
Non-removable implants with metal parts near target lesion
Myocardial infarction within 3 months prior to enrollment
Not suitable for general endotracheal anesthesia
Any patient greater than 18 years of age that the treating physician believes that ablation of their soft tissue would be feasible in the care of their pancreatic cancer.
Cohort
Prospective
Registry
Other interventionAdverse Events
Prospective collection of All Adverse Events that will be categorized as either IRE related or Non-IRE related and will be graded per CTCAE v4.0
Overall Survival
Capture overall survival in patients treated with IRE for their pancreatic tumors
Click on the lead sponsor to view all of their trials.
University of Louisville
Lead sponsor
The Americas Hepato-Pancreato-Biliary Association
Collaborator
